Top 5 stories on new drugs for HIV prevention and treatment from CROI 2023
Top 5 HIV treatment stories from CROI 2023
Rilpivirine resistance may be barrier to long-acting injectable treatment in South Africa
Lenacapavir plus broadly neutralising antibodies may offer twice-yearly treatment option
San Francisco shows that long-acting cabotegravir and rilpivirine may be feasible for people without viral suppression
Switching to injectable cabotegravir and rilpivirine rarely affects body weight
The people who need injectable HIV drugs most are the ones who can’t get them, BHIVA told
Do broadly neutralising antibodies really have a future in treating HIV?
Who is at risk of injectable treatment failure?
